LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Search

Neoleukin Therapeutics Inc

Fechado

0

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Neoleukin Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de nov. de 2025, 23:51 UTC

Ganhos

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 de nov. de 2025, 23:10 UTC

Ganhos

DBS Third Quarter Net Dips 2.0%

5 de nov. de 2025, 22:55 UTC

Ganhos

Arm Holdings 2Q Profit Climbs on Record Demand

5 de nov. de 2025, 22:23 UTC

Ganhos

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 de nov. de 2025, 23:52 UTC

Ganhos

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 de nov. de 2025, 23:49 UTC

Ganhos

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 de nov. de 2025, 23:49 UTC

Ganhos

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 de nov. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 de nov. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 de nov. de 2025, 23:12 UTC

Ganhos

Nutrien 3Q Adj EPS 97c >NTR.T

5 de nov. de 2025, 23:11 UTC

Ganhos

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 de nov. de 2025, 23:10 UTC

Ganhos

Nutrien 3Q Sales $6.01B >NTR.T

5 de nov. de 2025, 23:10 UTC

Conversa de Mercado
Ganhos

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 de nov. de 2025, 23:10 UTC

Ganhos

Nutrien 3Q EPS 96c >NTR.T

5 de nov. de 2025, 23:04 UTC

Ganhos

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 de nov. de 2025, 23:03 UTC

Conversa de Mercado

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 de nov. de 2025, 22:55 UTC

Conversa de Mercado

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 de nov. de 2025, 22:55 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 de nov. de 2025, 22:51 UTC

Ganhos

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 de nov. de 2025, 22:50 UTC

Ganhos

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 de nov. de 2025, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 de nov. de 2025, 22:43 UTC

Conversa de Mercado
Ganhos

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 de nov. de 2025, 22:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de nov. de 2025, 22:36 UTC

Conversa de Mercado

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 de nov. de 2025, 22:20 UTC

Conversa de Mercado

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 de nov. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 de nov. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 de nov. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Responds to Delaware Chancery Court Ruling

5 de nov. de 2025, 22:01 UTC

Ganhos

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 de nov. de 2025, 22:01 UTC

Ganhos

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Comparação entre Pares

Variação de preço

Neoleukin Therapeutics Inc Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Informação Financeira

$

help-icon Live chat